About Adial Pharmaceuticals, Inc - Common Stock (ADIL)
Adial Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for the treatment of addiction and related disorders. The company is primarily engaged in the research and clinical development of its lead product candidate, which aims to reduce the risk of relapse in patients with alcohol use disorder. Adial utilizes a patient population-centric approach to address significant unmet medical needs in substance use disorders through its proprietary technology and scientific expertise. By leveraging partnerships and conducting clinical trials, Adial is committed to advancing solutions that improve the lives of individuals affected by addiction. Read More
Adial Pharmaceuticals jumped to its highest level since February after receiving a U.S. patent for its precision medicine approach to treating addiction. The patent supports the use of AD04 in patients with specific genetic markers.
Adial Pharmaceuticals received a U.S. patent for genetic marker-based treatment methods and completed a pharmacokinetics study supporting its Phase 3 trial.
Adial Pharmaceuticals completes PK study for AD04 in AUD, meeting FDA requirements and preparing for Phase 3 trial. Data supports 505(b)(2) application.
Adial Pharmaceuticals secures a new patent allowance for AD04, enhancing its precision medicine approach for treating alcohol use disorder. Topline results from AD04's latest study are expected in Q4 2024.
Adial Pharmaceuticals has partnered with Boudicca Dx to advance the regulatory and technical strategy for its companion diagnostic test for AD0 for Alcohol Use Disorder. This collaboration is pivotal for Adial's upcoming Phase 3 trial.
Adial Pharmaceuticals announces the completion of the pharmacokinetics study dosing for AD04, their lead investigational treatment for Alcohol Use Disorder in heavy drinking patients. Topline results expected in Q4 2024 will inform Phase 3 clinical trial plans.
